Newly launched with a $90m series A funding round, the company is taking the idea behind KRAS G12C inhibitors to another level.

PacBio's TRGT can sequence broader sections of DNA, giving scientists and clinicians better odds of spotting repeated sections of DNA linked to disease.

The German group is optimistic evobrutinib can be a blockbuster in multiple sclerosis and has adapted its pivotal trial to cope with disruption caused by the war in Ukraine.

Torrent’s $245m acquisition of Curatio Healthcare has moved it up a rank to No.7 in the overall Indian pharmaceutical market apart from making it the market leader in cosmetic dermatology. While it’s a pricey deal, factors like growing prevalence of skin diseases and shift towards e-commerce bode well for future revenue growth in a nascent market